Targeting the Complement Cascade: A Novel Therapeutic Strategy for Metastatic Melanoma

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1103951

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The incidence of melanoma is increasing world-wide, and Queensland has the highest rate of melanoma in the world. Despite advances in treatment, the 3-year survival rate for metastatic melanoma remains extremely low. This project builds on our recent research demonstrating a role for a key component of the innate immune system (complement C3a) in melanoma growth. Specifically we seek to investigate the potential of C3a as a therapeutic target for metastatic melanoma.

Funded Activity Details

Start Date: 01-01-2016

End Date: 01-01-2018

Funding Scheme: Project Grants

Funding Amount: $546,496.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Tumour Immunology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

complement | melanoma | neutrophils | therapeutic target | tumour metastases

Related Links